These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24066727)

  • 1. Safety profile of the yellow fever vaccine Stamaril®: a 17-year review.
    Cottin P; Niedrig M; Domingo C
    Expert Rev Vaccines; 2013 Nov; 12(11):1351-68. PubMed ID: 24066727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse event reports following yellow fever vaccination.
    Lindsey NP; Schroeder BA; Miller ER; Braun MM; Hinckley AF; Marano N; Slade BA; Barnett ED; Brunette GW; Horan K; Staples JE; Kozarsky PE; Hayes EB
    Vaccine; 2008 Nov; 26(48):6077-82. PubMed ID: 18809449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced safety surveillance of STAMARIL® yellow fever vaccine provided under the expanded access investigational new drug program in the USA.
    Rojas A; Hachey W; Kaur G; Korejwo J; Muhammad R
    J Travel Med; 2023 Nov; 30(7):. PubMed ID: 37000007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse event reports following yellow fever vaccination, 2007-13.
    Lindsey NP; Rabe IB; Miller ER; Fischer M; Staples JE
    J Travel Med; 2016 May; 23(5):. PubMed ID: 27378369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of the risks and benefits of yellow fever vaccination including some new analyses.
    Monath TP
    Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How many published cases of serious adverse events after yellow fever vaccination meet Brighton Collaboration diagnostic criteria?
    Thomas RE; Spragins W; Lorenzetti DL
    Vaccine; 2013 Dec; 31(52):6201-9. PubMed ID: 24436960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of the yellow Fever vaccine: a retrospective study.
    Nordin JD; Parker ED; Vazquez-Benitez G; Kharbanda EO; Naleway A; Marcy SM; Molitor B; Kuckler L; Baggs J
    J Travel Med; 2013; 20(6):368-73. PubMed ID: 24118538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.
    Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
    Vaccine; 2011 Jun; 29(28):4544-55. PubMed ID: 21549787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of two yellow fever vaccines for routine immunization programs in Argentina.
    Ripoll C; Ponce A; Wilson MM; Sharif N; Vides JB; Armoni J; Teuwen DE
    Hum Vaccin; 2008; 4(2):121-6. PubMed ID: 18382132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.
    Breugelmans JG; Lewis RF; Agbenu E; Veit O; Jackson D; Domingo C; Böthe M; Perea W; Niedrig M; Gessner BD; Yactayo S;
    Vaccine; 2013 Apr; 31(14):1819-29. PubMed ID: 23395587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review.
    Rafferty E; Duclos P; Yactayo S; Schuster M
    Vaccine; 2013 Dec; 31(49):5798-805. PubMed ID: 24079979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models.
    Piras-Douce F; Raynal F; Raquin A; Girerd-Chambaz Y; Gautheron S; Sanchez MEN; Vangelisti M; Mantel N
    Vaccine; 2021 Mar; 39(13):1846-1856. PubMed ID: 33685778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reporting rates of yellow fever vaccine 17D or 17DD-associated serious adverse events in pharmacovigilance data bases: systematic review.
    Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
    Curr Drug Saf; 2011 Jul; 6(3):145-54. PubMed ID: 22122389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX.
    Kitchener S
    Vaccine; 2004 Jun; 22(17-18):2103-5. PubMed ID: 15149765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more.
    Miyaji KT; Luiz AM; Lara AN; do Socorro Souza Chaves T; Piorelli Rde O; Lopes MH; Sartori AM
    Hum Vaccin Immunother; 2013 Feb; 9(2):277-82. PubMed ID: 23291944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yellow fever vaccination: how much is enough?
    Massad E; Coutinho FA; Burattini MN; Lopez LF; Struchiner CJ
    Vaccine; 2005 Jun; 23(30):3908-14. PubMed ID: 15917112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yellow fever 17D vaccine safety and immunogenicity in the elderly.
    Monath TP; Cetron MS; McCarthy K; Nichols R; Archambault WT; Weld L; Bedford P
    Hum Vaccin; 2005; 1(5):207-14. PubMed ID: 17012867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yellow fever vaccine usage in the United States and risk of neurotropic and viscerotropic disease: A retrospective cohort study using three healthcare databases.
    Ledlie S; Ricci C; Pan C; Rojas A; Khromava A; Li L
    Vaccine; 2022 Jan; 40(5):742-751. PubMed ID: 34996642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse events following yellow fever immunization: Report and analysis of 67 neurological cases in Brazil.
    Martins Rde M; Pavão AL; de Oliveira PM; dos Santos PR; Carvalho SM; Mohrdieck R; Fernandes AR; Sato HK; de Figueiredo PM; von Doellinger Vdos R; Leal Mda L; Homma A; Maia Mde L
    Vaccine; 2014 Nov; 32(49):6676-82. PubMed ID: 24837504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD).
    Seligman SJ
    Vaccine; 2014 Oct; 32(44):5769-75. PubMed ID: 25192973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.